Conor Announces Positive Angiographic Results for EuroSTAR
Conor Medsystems presented angiographic and clinical data from the company's pivotal EuroSTAR study evaluating its CoStar cobalt chromium paclitaxel-eluting stent in a complex patient cohort.
The six-month follow-up data, demonstrating positive angiographic and clinical results for the treatment of single or multiple de novo lesions in native coronary arteries, were presented at the DES Revolution IV, a Cardiovascular Research Foundation-sponsored symposium immediately preceding the American College of Cardiology meeting in Orlando, Fla.
A total of 176 lesions were treated in 145 patients using the CoStar stent formulated to release a therapeutic dose of 10 mcg of paclitaxel over approximately 30 days (based on in vitro measurements). At six-month follow-up, the in-stent binary restenosis rate was 3.4 percent and the in-stent late loss was 0.26 mm. The in-segment binary restenosis rate was 4.7 percent and the in-segment late loss was 0.07 mm. As previously reported, the target lesion revascularization rate was 1.7 percent and the rate of cumulative major adverse cardiac events was 4.8 percent.
Upcoming Events
-
21Oct